Enkephalin Degrading Enzymes: Metalloproteases with High Potential for Drug Development

Author(s): Tejinder Pal Khaket, Jasbir Singh, Pooja Attri, Suman Dhanda

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 2 , 2012

Become EABM
Become Reviewer
Call for Editor


Enkephalins play a great role in management of pain, blood pressure, hypertension and cardiovascular diseases. Enkephalins are short-lived molecules being rapidly hydrolyzed following their synaptic release by enkephalin degrading enzymes. The inhibitors of enkephalin degrading enzymes are able to prolong the duration of action of enkephalins. This review will focus on the inhibitors of enkephalin degrading enzymes as a novel therapeutic approach for cancer itself and also in cancer and neuropathic pain management with discussion on the present status and future directions for a new class of drugs.

Keywords: Enkephalins, dipeptidylpeptidase-III, aminopeptidase N, neutral endopeptidase, angiotensin converting enzyme, puromycin sensitive enzyme, carboxypeptidase A6 and pain, hypertension, enkephalin degrading enzymes, stress

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [220 - 230]
Pages: 11
DOI: 10.2174/138161212799040547
Price: $65

Article Metrics

PDF: 14